Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 15/20 | 0.65 |
| ▸ | IKZF1 | Q13422 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24789318 | 0.91 | IKZF2 (0.65) | IKZF2IKZF1 | |
| SCHEMBL24790253 | 0.91 | IKZF2 (0.65) | IKZF2IKZF1 | |
| SCHEMBL20765334 | 0.91 | IKZF2 (0.78) | IKZF2IKZF1 | |
| SCHEMBL26552787 | 0.91 | IKZF1 (0.66) | IKZF2IKZF1 | |
| SCHEMBL24790788 | 0.91 | IKZF2 (0.61) | IKZF2IKZF1 | |
| SCHEMBL24789023 | 0.90 | IKZF2 (0.63) | IKZF2IKZF1 | |
| SCHEMBL25617951 | 0.90 | IKZF2 (0.63) | IKZF2IKZF1 | |
| SCHEMBL25615917 | 0.90 | IKZF2 (0.63) | IKZF2IKZF1 | |
| SCHEMBL25617053 | 0.90 | IKZF1 (0.64) | IKZF2IKZF1 | |
| SCHEMBL20935997 | 0.89 | IKZF2 (0.62) | IKZF2IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230332104-A1 | ZBTB32 INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-10-19 | — | — | US | disclosed |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4183782-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DI ONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2023-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230332104-A1 | ZBTB32 INHIBITORS AND USES THEREOF | IKZF2, IKZF3, BAZ2B | IKZF2 1/4885IKZF1 38/4885 |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | IKZF2 2/4885IKZF1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.